UNMC Seeks Participants for Alzheimer’s Disease Prevention Trial
The University of Nebraska Medical Center recently launched an Alzheimer’s disease (AD) research study and is recruiting subjects for the trial.
The study, which is headed by Daniel Murman, M.D., professor in the UNMC Department of Neurological Sciences and director of the Memory Disorders & Behavioral Neurology Program, is called The Alzheimer’s Prevention Initiative (API) Generation Study.
Dr. Murman explains, “Previous trials suggest that we must treat Alzheimer’s disease very early to be successful in slowing down the disease process. The Generation Study is looking for normal adults between the ages of 60 and 75 years, who are at increased risk of developing symptoms of AD because of a genetic subtype. The trial involves medication designed to decrease a protein called beta amyloid in the brain, which is thought to be an important cause of AD.”
Dr. Murman also has been involved in Alzheimer’s research efforts through other nationally funded clinical trial efforts in the past, including the Expedition 3 trial for patients with mild AD, and the Nobel Study for patients with mild to moderate AD, and continues to be involved in the Anti-Amyloid Treatment in Asymptomatic AD (A4) study.
Additional information about participation in the clinical trial featured above can be found in the below resources: Alzheimer’s Association Trial Match at www.alz.org/trialmatch; UNMC Clinical Trial Database at net.unmc.edu/ctsearch/index_unmc.php; Generation Study at www.generationstudy.com; and www.endalznow.org/GeneMatch.